



**Investment Objective**

Leverage Shares 2x Pfizer ETP is an Exchange-Traded Product (ETP) fully backed by physical assets. The ETP tracks NYSE Leveraged 2x PFE Index, providing two times the daily performance of Pfizer Inc.’s common stock, PFE, adjusted to reflect the fees and costs inherent to maintain a leveraged position in the stock.

For example, if Pfizer rises by 1% over a day, then the ETP will rise by 2%, excluding fees. However if the Pfizer falls by 1% over a day, then the ETP will fall by 2%, excluding fees.

**Key Features**

- Opportunity to magnify returns in one simple trade.
- Liquid. Trades like an equity on exchange, with multiple authorised participants (APs) and market makers (MMs).
- You cannot lose more than the amount invested, and an intraday rebalance mechanism is designed to cushion the largest intra-day falls.
- Simple to trade, no need for futures, no need to use margin account.
- Transparent structure with credit risk effectively negated. Each series of the SPV has physical ownership of the underlying stocks and does not use derivatives.
- Is independent and managed by industry experts.

**Key Risks**

- Investing in Short and Leveraged ETPs is only suitable for sophisticated and/or informed traders who understand leverage, daily rebalancing and compounded daily returns and are willing to magnify potential losses.
- Investors can lose the full value of their initial investment, however they cannot lose more than their initial investment.
- Losses are magnified due to the nature of leveraged returns. Therefore, Short and Leveraged ETPs are only suitable for investors willing to take a high level of risk.
- Daily compounding may result in returns which an investor may not expect, if the investor has not fully understood how a Leverage Shares ETP works.
- Due to daily rebalancing and compounding, returns measured over periods longer than one day may differ from the underlying index return over those periods.
- In the event a swap counterparty defaults, the proceeds from realisation of the collateral may be less than what the investor expects.
- Investors should only use Leverage Shares ETPs if they have the ability to monitor their positions daily or during the day.
- Please see the risks factors section of the Prospectus for a more detailed discussion of the potential risks.

**PRODUCT INFORMATION**

Product Name	Leverage Shares 2x Pfizer ETP
Underlying Security	US PFE
Leverage Factor	2x
Physical Assets Owned	Yes
Trading/Base Currency	USD/USD
ISIN	IE00BD09ZZ70

**LISTING AND TRADING INFORMATION**

Exchange	London Stock Exchange
Exchange Ticker	PFE2
SEDOL	BD09ZZ7
Bloomberg Code	PFE2 LN Equity
Additional Listings	2PFE

**ADDITIONAL INFORMATION**


Issuer	Leverage Shares, PLC
Trustee	Link Corporate Trustees (UK) Limited
Margin Provider	Interactive Brokers LLC
Margin Rate	Fed Funds Effective (Overnight Rate) +1%
Annual Management Fee	0.75%
SIPP/ISA	Eligible
UK Fund reporting Status	No

**INDEX INFORMATION**

Index	NYSE Leveraged 2x PFE Index
Index Provider	NYSE
Index Currency	USD
Index Ticker	NY2LPFE

A more complete description of the product, service providers and relevant regulatory factors is available in the Prospectus ([www.leverageshares.com](http://www.leverageshares.com)), and it is recommended that investors refer to it as their main reference point.

**Risk and Reward Profile**



N.B. This diagram is not a UCITS synthetic risk & reward indicator and is enclosed for information purposes only

## Contact Information

Contact us at via email at [info@leverageshares.com](mailto:info@leverageshares.com) or on Twitter at @LeverageShares. More information on Leverage Shares can we found online at [www.leverageshares.com](http://www.leverageshares.com).

## Disclaimer

Leverage Shares ETPs are only intended for sophisticated traders who understand the associated risks and are able to monitor their positions on an intraday basis. Please consult an investment adviser to determine whether or not the products are suitable for you. Traders should also review the Base Prospectus and the Leverage Shares educational materials carefully before considering the ETPs.

## General

This financial promotion has been issued and approved for the purpose of section 21 of the Financial Services and Markets Act 2000 by Resolution Compliance Limited(RCL) which is authorised and regulated by the United Kingdom Financial Conduct Authority ("FCA"). The products discussed in this document are issued by LEVERAGE SHARES PLC (the "Issuer").

## No investment advice

Leverage Shares PLC is required by the FCA to clarify that it is not acting for you in any way in relation to the investment or investment activity to which this financial promotion relates. In particular, LEVERAGE SHARES PLC will not provide any investment services to you and or advise you on the merits of, or make any recommendation to you in relation to, the terms of any transaction. No representative of LEVERAGE SHARES PLC is authorised to behave in any way which would lead you to believe otherwise. LEVERAGE SHARES PLC is not, therefore, responsible for providing you with the protections afforded to its clients and you should seek your own independent legal, investment and tax or other advice as you see fit.

## No offer for sale

The information contained in this financial promotion is neither an offer for sale nor a solicitation of an offer to buy securities. This financial promotion should not be used as the basis for any investment decision.

## Risk Warnings

The value of an investment in ETPs may go down as well as up and past performance is not a reliable indicator of future performance. An investment in ETPs is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs offering daily leveraged or daily short exposures ("Leveraged ETPs") are products which feature specific risks that prospective investors should understand before investing in them.

Securities issued by the Issuer are products involving a significant degree of risk and may not be suitable for all types of investor. Any decision to invest should be based on the information contained in the prospectus of the Issuer (or any supplements thereto) which includes, inter alia, information on certain risks associated with an investment. The price of any securities may go up or down and an investor may not get back the amount invested. Securities are priced in US Dollars/Euros/Pounds and the value of the investment in other currencies will be affected by exchange rate movements.

Short and leveraged exchange-traded products are only intended for investors who understand the risks involved in investing in a product with short and/or leveraged exposure and who intend to invest on a short-term basis. Any investment in short and/or leveraged products should be monitored on a daily basis to ensure consistency with your investment strategy. You should understand that investments in short and/or leveraged exchange-traded products held for a period of longer than one day may not provide returns equivalent to the return from the relevant unleveraged investment multiplied by the relevant leverage factor.

Potential losses in short and/or leveraged exchange-traded products may be magnified in comparison to investments that do not incorporate these strategies. Please refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in short and/or leveraged exchange-traded products. You should consult an independent investment adviser prior to making an investment in short and/or leveraged exchange-traded products in order to determine its suitability to your circumstances.

## Prospectus

Investors should refer to the section entitled "Risk Factors" in the relevant prospectus for further details of these and other risks associated with an investment in the securities offered by the Issuer.

The FCA/Central Bank of Ireland has delivered to the regulators listed below certificates of approval attesting that the prospectus of the Issuer has been drawn up in accordance with European Directive 2003/71/EC as amended by European Directive 2010/73/EU.

The prospectus (and any supplements thereto) of the Issuer has been passported from the Ireland INTO xxxx and has been filed with the following National Competent Authorities, Financial Conduct Authority(United Kingdom).

Investors should read the prospectus of the Issuer ("Prospectus") before investing and should refer to the section of the Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in this product.